Search our team at AdventHealth Research Institute
-
NCT06469944
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents with Pembrolizumab (MK-3475) in Participants with Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment [KEYMAKER-U06]
This study is not currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer Research -
NCT06203600
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following questions: Can adding a drug to the usual treatment for advanced stomach and esophageal cancers make it less likely that these cancers will grow or...
-
NCT04248452
EA2183, A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric...
-
NCT06346392
D9802C00001 (CLARITY GC01): A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaWe are doing this study to learn more about: the effectiveness and safety of the investigational study drug AZD0901 compared to a standard therapy that will be selected by your study doctor per your...
-
NCT06356311
MK2870-015: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaTo compare MK-2870 to TPC
with respect to OS.To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR. To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed...